Stephenl Hoffman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

In a report published on March 21, 2024 in EMBO Molecular Medicine (A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion) investigators at Seattle Children's Research Institute and Sanaria Inc. describe the development of a whole malaria parasite vaccine strain that infects the liver, develops to the late liver stage, and then gets completely stuck and cannot burst out of the liver to cause symptomatic blood infection.

Scientists from Sanaria Inc., and collaborators at multiple institutions publish results in Nature reporting "In vitro production of infectious Plasmodium falciparum sporozoites."

Malaria parasite. Photo: SENSISEEDSTwo United States (U.S.) Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedented high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. According to the study published, yesterday, in the journal Nature, by A. Mwakingwe-Omari et al and titled ‘Two chemo-attenuated PfSPZ malaria vaccines induce sterile hepatic immunity’, the vaccine combines live parasites with either of two widely used antimalarial drugs- an approach termed chemoprophylaxis vacci...

Sanaria researchers make progress in the development of highly protective malaria vaccine Researchers from Sanaria ® Inc. and the National Institutes of Health (NIH) are making progress in the development of highly protective malaria vaccines. In an article published today in Nature, Sanaria's PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company's Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been ac...

Novel candidate malaria vaccine confers high levels of durable protection Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs--an approach termed chemoprophylaxis vaccination. A Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country. If the approach proves successful there, chemoprophylaxis vaccinat...